Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Andecaliximab |
Synonyms | |
Therapy Description |
Andecaliximab (GS-5745) is a monoclonal antibody that binds to and inhibits matrix metalloproteinase 9 (MMP-9), which may lead to inhibition of matrix degradation and tumor metastasis (PMID: 25961845, PMID: 29691300). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Andecaliximab | GS-5745 | Andecaliximab (GS-5745) is a monoclonal antibody that binds to and inhibits matrix metalloproteinase 9 (MMP-9), which may lead to inhibition of matrix degradation and tumor metastasis (PMID: 25961845, PMID: 29691300). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02545504 | Phase III | Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Andecaliximab | GS-5745 With mFOLFOX6 as First Line Treatment for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma | Completed | USA | TUR | ROU | POL | ITA | HUN | GBR | FRA | ESP | DEU | CZE | BEL | AUS | 3 |
NCT01803282 | Phase I | Andecaliximab Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Carboplatin + Pemetrexed Disodium Fluorouracil + Irinotecan + Leucovorin Gemcitabine + Nab-paclitaxel Carboplatin + Paclitaxel Paclitaxel Bevacizumab | Safety and Tolerability Study in Solid Tumors | Completed | USA | 0 |